Search results
Sep 2, 2020 · Gavin Gordon, Ph.D. has joined Akoya as VP of Clinical Market Development, bringing expertise in cancer diagnostics, translational research and partnerships with pharma and biotech companies. In his new role, Dr. Ramachandran is responsible for developing a robust roadmap and commercialization strategy for Akoya’s platforms.
Sep 2, 2020 · Gavin Gordon, Ph.D. has joined Akoya as VP of Clinical Market Development, bringing expertise in cancer diagnostics, translational research and partnerships with pharma and biotech companies.
Gavin J Gordon's 56 research works with 3,235 citations and 2,251 reads, including: Genetic alterations in esophageal cancers: Detection by next-generation sequencing and potential for...
May 11, 2023 · He is also the co-chair of The Digital, Data and Design (D^3) Institute at Harvard at Harvard and former co-director of the program on the economics of digitization at The National Bureau of Economic Research.
Corporate Officer/Principal at Akoya Biosciences, Inc., Discover Gavin Gordon's known position history, network and 27 relationships. Find out about his known public assets.
Dana-Farber/Harvard Cancer Center (DF/HCC), an NCI-designated comprehensive cancer center, was founded to integrate and build upon the collective talent and resources of the Harvard cancer research community.
Jun 24, 2016 · Harvard Staff Writer. June 24, 2016 8 min read. University initiates patent infringement suits to protect inventors’ rights in atomic layer deposition technology. In the late 1990s, computer-chip makers were facing a Moore’s Law dead end, and Harvard chemist Roy Gordon thought he could help.
